Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 1
1986 1
1990 3
1992 3
1995 1
1996 1
1997 2
1998 5
1999 2
2000 3
2001 3
2002 2
2003 1
2004 4
2005 3
2006 7
2007 5
2008 7
2009 3
2010 4
2011 5
2012 9
2013 9
2014 7
2015 3
2016 5
2017 7
2018 4
2019 5
2020 7
2021 7
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25963722

118 results

Results by year

Filters applied: . Clear all
Page 1
Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship.
Kasteleijn-Nolst Trenité D, Brandt C, Mayer T, Rosenow F, Schmidt B, Steinhoff BJ, Gardin A, Imbert G, Johns D, Sagkriotis A, Kucher K. Kasteleijn-Nolst Trenité D, et al. Epilepsia. 2015 Jun;56(6):924-32. doi: 10.1111/epi.13008. Epub 2015 May 11. Epilepsia. 2015. PMID: 25963722 Free article. Clinical Trial.
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.
Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC; BGG492 Study Group. Gomez-Mancilla B, et al. Cephalalgia. 2014 Feb;34(2):103-13. doi: 10.1177/0333102413499648. Epub 2013 Aug 20. Cephalalgia. 2014. PMID: 23963355 Clinical Trial.
Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study.
Trenité DG, French JA, Hirsch E, Macher JP, Meyer BU, Grosse PA, Abou-Khalil BW, Rosenfeld WE, van Gerven J, Novak GP, Parmeggiani L, Schmidt B, Gibson D, Guerrini R. Trenité DG, et al. Epilepsy Res. 2007 May;74(2-3):193-200. doi: 10.1016/j.eplepsyres.2007.03.012. Epub 2007 Apr 19. Epilepsy Res. 2007. PMID: 17448639 Clinical Trial.
Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study.
Kucher K, Johns D, Wagner F, Abd-Elaziz K, Derne C, Sverdlov O, Pfister CU, Langguth B. Kucher K, et al. Prog Brain Res. 2021;260:423-440. doi: 10.1016/bs.pbr.2020.12.004. Epub 2021 Jan 20. Prog Brain Res. 2021. PMID: 33637230 Clinical Trial.
118 results